Abstract: OBJECTIVE To observe the effect of rosuvastatin on plasma tissue factor (TF) and tissue factor pathway inhibitor(TFPI) in patients with hematencephalon. METHODS One hundred patients with cerebral hemorrhage from January 2015 to January 2016 were enrolled as case group, and a total of 100 healthy persons were selected as normal group at the same time. The patients were randomly divided into observation group (51 cases) and control group (49 cases). The control group was given routine treatment such as to improve blood press and encephaledema, to adjust metabolic system of phosphorus and calcium, to drip mannitol in intravenous after treatment. The observation group was given rosuvastatin (p.o 20 mg, qd, last for 3 month) on the basis of control group. Levels of TF and TFPI were compared between case group and normal group before treatment, and levels of TF, TFPI and serum lipid were compared between control group and observation group before and after treatment. RESULTS The levels of TF and TFPI in case group were significantly higher than those in normal group before treatment. The levels of TF, TFPI and serum lipid in observation group were not significantly different from those in control group before treatment. After treatment for 3 months, the levels of TF in observation group were significantly lower than those in control group; the levels of TFPI in observation group were significantly higher than those in control group. Correlation analysis of Pearson indicated that there were no correlation between the level of TF or TFPI with serum lipid levels. There was no significantly different in adverse reaction rates between observation group and control group. CONCLUSION Rosuvastatin could decrease the levels of TF and increased the level of TFPI in patients with hematencephalon. Therefore, rosuvastatin could balance coagulation for patients with hematencephalon.